Activity of novel Cdc25 inhibitors and preliminary evaluation of their potentiation of chemotherapeutic drugs in human breast cancer cells

Life Sciences

Volumn 82, Issue 5-6, 2008, Pages 315-323

  Brault, Laurent ^a   Bagrel, Denyse ^a  

^a UFR SciFA   (France)

Author keywords

Adriamycin; Breast cancer; Cdc25 inhibitor; Cell cycle; Cisplatin; Maleic anhydride derivatives

Indexed keywords

CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 25; CISPLATIN; DOXORUBICIN; MALEIC ANHYDRIDE; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOXICITY; HUMAN; HUMAN CELL; RESPIRATORY BURST;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CDC25 PHOSPHATASES; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; G0 PHASE; G1 PHASE; HUMANS; MALEIC ANHYDRIDES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; VINCRISTINE;

MAMMALIA;

EID: 38349051788     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.12.001     Document Type: Article

References (24)

1. Agner J., Falck J., Lukas J., and Bartek J. Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway. Experimental Cell Research 302 (2005) 162-169
2. Aoyagi Y., Masuko N., Ohkubo S., Kitade M., Nagai K., Okazaki S., Wierzba K., Terada T., Sugimoto Y., and Yamada Y. A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity. Cancer Science 96 (2005) 614-619
3. Boutros R., Lobjois V., and Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets?. Nature Reviews. Cancer 7 (2007) 495-507
4. Brault L., Denancé M., Banaszak E., El Maadidi S., Battaglia E., Bagrel D., and Samadi M. Synthesis and biological evaluation of dialkylsubstituted maleic anhydrides as novel inhibitors of Cdc25 dual specificity phosphatases. European Journal of Medicinal Chemistry 42 (2007) 243-247
5. Brezak M.C., Quaranta M., Mondesert O., Galcera M.O., Lavergne O., Alby F., Cazales M., Baldin V., Thurieau C., Harnett J., Lanco C., Kasprzyk P.G., Prevost G.P., and Ducommun B. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Resarch 64 (2004) 320-3325
6. Brisson M., Nguyen T., Vogt A., Yalowich J., Giorgianni A., Tobi D., Bahar I., Stephenson C.R., Wipf P., and Lazo J.S. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Molecular Pharmacology 66 (2004) 824-833
7. Cangi M.G., Cukor B., Soung P., Signoretti S., Moreira Jr. G., Ranashinge M., Cady B., Pagano M., and Loda M. Role of the Cdc25A phosphatase in human breast cancer. Journal of Clinical Investigation 106 (2000) 753-761
8. Ciftci K., Su J., and Trovitch P.B. Growth factors and chemotherapeutic modulation of breast cancer cells. Journal of Pharmacy and Pharmacology 55 (2003) 1135-1141
9. Davezac N., Ducommun B., and Baldin V. Role of CDC25 phosphatases in the control of proliferation. Pathologie-Biologie (Paris) 48 (2000) 182-189
10. Galaktionov K., Chen X., and Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382 (1996) 511-517
11. Gasparotto D., Maestro R., Piccinin S., Vukosavljevic T., Barzan L., Sulfaro S., and Boiocchi M. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Research 57 (1997) 2366-2368
12. Gunasekera S.P., McCarthy P.J., Kelly-Borges M., Lobkovsky E., and Clardy J. Dysidiolide: a novel protein phosphatase inhibitor from the caribbean sponge Dysidea etheria de Laubenfels. Journal of the American Chemical Society 118 (1996) 8759-8760
13. Heath-Engel H.M., and Shore G.C. Mitochondrial membrane dynamics, cristae remodelling and apoptosis. Biochimica et Biophysica Acta 1763 (2006) 549-560
14. Kristjansdottir K., and Rudolph J. Cdc25 phosphatases and cancer. Chemistry and Biology 11 (2004) 1043-1051
15. Lyon M.A., Ducruet A.P., Wipf P., and Lazo J.S. Dual-specificity phosphatases as targets for antineoplastic agents. Nature Reviews. Drug Discovery 1 (2002) 961-976
16. McCain D.F., Catrina I.E., Hengge A.C., and Zhang Z.Y. The catalytic mechanism of Cdc25A phosphatase. Journal of Biological Chemistry 277 (2002) 11190-11200
17. Nilsson I., and Hoffmann I. Cell cycle regulation by the Cdc25 phosphatase family. Progress in Cell Cycle Research 4 (2000) 107-114
18. Otto A.M., Paddenberg R., Schubert S., and Mannherz H.G. Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. Journal of Cancer Research and Clinical Oncology 122 (1996) 603-612
19. Parone P.A., and Martinou J.C. Mitochondrial fission and apoptosis: an ongoing trial. Biochimica et Biophysica Acta 1763 (2006) 522-530
20. Russell P., and Nurse P. Cdc25+ functions as an inducer in the mitotic control of fission yeast. Cell 45 (1986) 145-153
21. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Research 60 (2000) 3689-3695
22. Shimazawa R., Suzuki T., Dodo K., and Shirai R. Design and synthesis of dysidiolide analogs from vitamin D3: novel class of Cdc25A inhibitors. Bioorganic and Medicinal Chemistry Letters 14 (2004) 3291-3294
23. Wesierska-Gadek J., Gueorguieva M., and Horky M. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Polish Journal of Pharmacology 55 (2003) 895-902
24. Whelan R.D., Waring C.J., Wolf C.R., Hayes J.D., Hosking L.K., and Hill B.T. Over-expression of P-glycoprotein and glutathione S-transferase pi in MCF-7 cells selected for vincristine resistance in vitro. International Journal of Cancer 52 (1992) 241-246